{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:34:45Z","timestamp":1787499285718,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.clinthera.2007.04.007","type":"journal-article","created":{"date-parts":[[2007,7,6]],"date-time":"2007-07-06T07:20:34Z","timestamp":1183706434000},"page":"588-601","source":"Crossref","is-referenced-by-count":78,"title":["Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study"],"prefix":"10.1016","volume":"29","author":[{"given":"David M.","family":"Simpson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2007.04.007_bib1","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00702-005-0300-x","article-title":"Evidencebased pharmacological treatment of neuropathic pain syndromes","volume":"112","author":"Beniczky","year":"2005","journal-title":"J Neural Transm"},{"key":"10.1016\/j.clinthera.2007.04.007_bib2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1468-1331.2004.00791.x","article-title":"EFNS guidelines on neuropathic pain assessment","volume":"11","author":"Cruccu","year":"2004","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.clinthera.2007.04.007_bib3","series-title":"Classification of Chronic Pain","first-page":"209","article-title":"IASP pain terminology","author":"International Association for the Study of Pain","year":"1994"},{"key":"10.1016\/j.clinthera.2007.04.007_bib4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3810\/hp.1998.10.114","article-title":"Neuropathic pain: New insights, new interventions","volume":"33","author":"Bennett","year":"1998","journal-title":"Hosp Pract"},{"key":"10.1016\/j.clinthera.2007.04.007_bib5","series-title":"Molecular Neurobiology of Pain","first-page":"109","article-title":"Neuropathic pain: An overview","author":"Bennett","year":"1997"},{"key":"10.1016\/j.clinthera.2007.04.007_bib6","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMe030014","article-title":"Opioids and chronic neuropathic pain","volume":"348","author":"Foley","year":"2003","journal-title":"N Engl j Med"},{"issue":"Suppl A","key":"10.1016\/j.clinthera.2007.04.007_bib7","doi-asserted-by":"crossref","first-page":"5A","DOI":"10.1155\/2006\/718098","article-title":"Prevalence of neuropathic pain and the need for treatment","volume":"11","author":"Morley-Forster","year":"2006","journal-title":"Pain Res Manag"},{"key":"10.1016\/j.clinthera.2007.04.007_bib8","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00002508-200211000-00001","article-title":"An overview of neuropathic pain: Syndromes, symptoms, signs, and several mechanisms","volume":"18","author":"Dworkin","year":"2002","journal-title":"Clin J Pain"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2007.04.007_bib9","first-page":"528","article-title":"Pharmacologic management part 1: Better-studied neuropathic pain diseases","volume":"5","author":"Backonja","year":"2004","journal-title":"Pain Med"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2007.04.007_bib10","first-page":"548","article-title":"Pharmacologic management part 2: Lesser-studied neuropathic pain diseases","volume":"5","author":"Backonja","year":"2004","journal-title":"Pain Med"},{"key":"10.1016\/j.clinthera.2007.04.007_bib11","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1001\/jama.293.24.3043","article-title":"Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: Systematic review and meta-analysis of randomized controlled trials","volume":"293","author":"Eisenberg","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2007.04.007_bib12","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1056\/NEJMe058039","article-title":"Combination therapy for neuropathic pain-which drugs, which combination, which patients?","volume":"352","author":"Raja","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2007.04.007_bib13","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1056\/NEJMoa021420","article-title":"Oral opioid therapy for chronic peripheral and central neuropathic pain","volume":"348","author":"Rowbotham","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2007.04.007_bib14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1191\/0269216304pm890oa","article-title":"Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey","volume":"18","author":"Caraceni","year":"2004","journal-title":"Palliat Med"},{"key":"10.1016\/j.clinthera.2007.04.007_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0885-3924(98)00045-1","article-title":"Characterization of breakthrough pain by hospice patients and their caregivers","volume":"16","author":"Fine","year":"1998","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clinthera.2007.04.007_bib16","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cncr.10249","article-title":"Episodic (breakthrough) pain: Consensus conference of an expert working group of the European Association for Palliative Care","volume":"94","author":"Mercadante","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2007.04.007_bib17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0304-3959(90)90004-W","article-title":"Breakthrough pain: Definition, prevalence and characteristics","volume":"41","author":"Portenoy","year":"1990","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2007.04.007_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0304-3959(99)00006-8","article-title":"Breakthrough pain: Characteristics and impact in patients with cancer pain","volume":"81","author":"Portenoy","year":"1999","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2007.04.007_bib19","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejpain.2004.06.001","article-title":"Breakthrough pain in malignant and non-malignant diseases: A review of prevalence, characteristics and mechanisms","volume":"9","author":"Svendsen","year":"2005","journal-title":"Eur J Pain"},{"key":"10.1016\/j.clinthera.2007.04.007_bib20","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jpain.2006.02.003","article-title":"Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain","volume":"7","author":"Portenoy","year":"2006","journal-title":"J Pain"},{"key":"10.1016\/j.clinthera.2007.04.007_bib21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1191\/026921601678576220","article-title":"Prevalence and characteristics of breakthrough pain in patients with nonmalignant terminal disease admitted to a hospice","volume":"15","author":"Zeppetella","year":"2001","journal-title":"Palliat Med"},{"key":"10.1016\/j.clinthera.2007.04.007_bib22","doi-asserted-by":"crossref","first-page":"347","DOI":"10.5055\/jom.2006.0051","article-title":"Breakthrough pain in opioid-treated patients with neuropathic pain","volume":"2","author":"Simon","year":"2006","journal-title":"J Opioid Manag"},{"key":"10.1016\/j.clinthera.2007.04.007_bib23","series-title":"APS Clinical Practice Guidelines Series, no 3","article-title":"Guideline for the Management of Cancer Pain in Adults and Children","author":"Miaskowski","year":"2005"},{"key":"10.1016\/j.clinthera.2007.04.007_bib24","first-page":"1","article-title":"Opioids for the management of breakthrough (episodic) pain in cancer patients","author":"Zeppetella","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2007.04.007_bib25","first-page":"354","article-title":"Consensus panel recommendations for the assessment and management of breakthrough pain: Part 2 management","volume":"30","author":"Bennett","year":"2005","journal-title":"P&T"},{"key":"10.1016\/j.clinthera.2007.04.007_bib26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0304-3959(02)00293-2","article-title":"Cancer breakthrough pain characteristics and responses to treatment at a VA medical center","volume":"101","author":"Hwang","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2007.04.007_bib27","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/01.ajp.0000210932.27945.4a","article-title":"A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioidtreated patients with cancer","volume":"22","author":"Portenoy","year":"2006","journal-title":"Clin J Pain"},{"key":"10.1016\/j.clinthera.2007.04.007_bib28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1185\/030079906X162818","article-title":"Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: A randomized, placebo-controlled study","volume":"23","author":"Portenoy","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2007.04.007_bib29","series-title":"Guideline for good clinical practice: ICH harmonised tripartite guideline","author":"European Medicines Agency","year":"2007"},{"key":"10.1016\/j.clinthera.2007.04.007_bib30","series-title":"Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain","author":"American Pain Society","year":"2007"},{"key":"10.1016\/j.clinthera.2007.04.007_bib31","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/jnci\/90.8.611","article-title":"Oral transmucosal fentanyl citrate: Randomized, double-blinded, placebocontrolled trial for treatment of breakthrough pain in cancer patients","volume":"90","author":"Farrar","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clinthera.2007.04.007_bib32","series-title":"Linear Models for Unbalanced Data","author":"Searle","year":"1987"},{"key":"10.1016\/j.clinthera.2007.04.007_bib33","series-title":"Generalized LinearModels","author":"McCullagh","year":"1989"},{"key":"10.1016\/j.clinthera.2007.04.007_bib34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0304-3959(03)00160-X","article-title":"Controlled-release oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy","volume":"105","author":"Watson","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2007.04.007_bib35","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1212\/01.WNL.0000057720.36503.2C","article-title":"Controlled-release oxycodone for pain in diabetic neuropathy: A ran domized controlled trial","volume":"60","author":"Gimbel","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2007.04.007_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00137696-200604010-00001","article-title":"Fentanyl effervescent buccal tablets: Enhanced buccal absorption","volume":"4","author":"Durfee","year":"2006","journal-title":"Am J Drug Deliv"},{"key":"10.1016\/j.clinthera.2007.04.007_bib37","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.2165\/00003088-200544120-00006","article-title":"Pharmacokinetics and dose proportionality of fentanyl ef fervescent buccal tablets in healthy volunteers","volume":"44","author":"Darwish","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2007.04.007_bib38","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.clinthera.2006.05.016","article-title":"Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1080 pg versus oral transmucosal fentanyl citrate 1600 pg and dose proportionality of FEBT 270 to 1300 microg: A single-dose, randomized, open-label, three-period study in healthy adult volunteers","volume":"28","author":"Darwish","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2007.04.007_bib39","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.clinthera.2006.05.015","article-title":"Pharmacokinetic properties of fentanyl effervescent buccal tablets: A phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers","volume":"28","author":"Darwish","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2007.04.007_bib40","series-title":"Poster presented at: 25th Annual Meeting of the American Pain Society","article-title":"Comparative bioavailability of the novel fentanyl effervescent buc cal tablet formulation: An open-label crossover study","author":"Darwish","year":"2006"},{"key":"10.1016\/j.clinthera.2007.04.007_bib41","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1191\/0269216304pm966oa","article-title":"Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: An open, multicentre, dose-titration and long-term use study","volume":"18","author":"Hanks","year":"2004","journal-title":"Palliat Med"},{"key":"10.1016\/j.clinthera.2007.04.007_bib42","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0885-3924(01)00306-2","article-title":"Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain","volume":"22","author":"Payne","year":"2001","journal-title":"J Pain Symptom Manage"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291807001075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291807001075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T00:49:01Z","timestamp":1556585341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291807001075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0149291807001075"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2007.04.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}